Core Viewpoint - The integration of artificial intelligence (AI) and biomedicine is accelerating drug development and reducing costs, with a focus on the Shanghai International Computational Biology Innovation Competition set to launch in June 2025 [1]. Group 1: Competition Overview - The competition will focus on the G protein-coupled receptor family, specifically the Hydroxycarboxylic Acid Receptor 1 (HCAR1), aiming to discover drug molecules that specifically target HCAR1 using AI computational methods [2]. - HCAR1 is identified as a potential target for anti-tumor drugs, with its abnormal activation linked to various pathological processes, including tumor progression [2]. - The competition will consist of three stages: registration, preliminary rounds, and finals, with separate evaluations for small molecules (HCAR1 antagonists) and large molecules (HCAR1-specific antibodies) [3]. Group 2: Industry Development - The launch of the competition aligns with Shanghai's goal to build an internationally influential biomedicine innovation hub, creating a world-class biomedicine industry cluster [4]. - The competition aims to create an innovative closed loop from basic discovery to technology validation and application, gathering resources from universities, research institutions, and CROs [4]. - By 2025, the Shanghai Computational Biology Innovation Development Action Plan aims to establish a comprehensive computational biology research paradigm and develop a biobig data platform, fostering talent and achieving breakthroughs in various fields [4]. Group 3: Impact on Drug Development - The competition is part of the action plan to connect industry development, encouraging universities and enterprises to showcase original products in algorithms, software, and structures [5]. - Such competitions are expected to alleviate the issue of "heavy on papers, light on translation" in innovative drug development, providing a source of innovation for globally competitive original drugs [5]. - The technological outcomes and collaborative effects generated by the competition are anticipated to be key drivers for upgrading the biomedicine industry in the city [5].